


<!DOCTYPE html>
<html lang="en">
<head><script src="//archive.org/includes/analytics.js?v=cf34f82" type="text/javascript"></script>
<script type="text/javascript">window.addEventListener('DOMContentLoaded',function(){var v=archive_analytics.values;v.service='wb';v.server_name='wwwb-app23.us.archive.org';v.server_ms=1449;archive_analytics.send_pageview({});});</script><script type="text/javascript" src="/static/js/wbhack.js?v=1531166943.0" charset="utf-8"></script>

<script type="text/javascript">
__wbhack.init('https://web.archive.org/web');
</script>
<link rel="stylesheet" type="text/css" href="/static/css/banner-styles.css?v=1531166943.0" />
<link rel="stylesheet" type="text/css" href="/static/css/iconochive.css?v=1531166943.0" />

<!-- End Wayback Rewrite JS Include -->  

        <title>ACR Appropriateness Criteria&amp;reg; local excision in rectal cancer. | National Guideline Clearinghouse</title>

    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width">
    <link rel="icon" href="/web/20180712201305im_/https://www.guideline.gov/UI/images/favicon-NGC.ico">
    <link rel="apple-touch-icon" sizes="180x180" href="/web/20180712201305im_/https://www.guideline.gov/UI/images/apple-touch-icon-NGC.png">
    <link rel="icon" type="image/png" href="/web/20180712201305im_/https://www.guideline.gov/UI/images/favicon-NGC-32x32.png" sizes="32x32">
    <link rel="icon" type="image/png" href="/web/20180712201305im_/https://www.guideline.gov/UI/images/favicon-NGC-16x16.png" sizes="16x16">
    <link rel="manifest" href="/web/20180712201305/https://www.guideline.gov/UI/images/manifest-NGC.json">
    <link rel="mask-icon" href="/web/20180712201305im_/https://www.guideline.gov/UI/images/safari-pinned-tab-NGC.svg" color="#1d4345">
    <meta name="theme-color" content="#ffffff">
    
<link href="/web/20180712201305cs_/https://www.guideline.gov/cassette.axd/stylesheet/8382974d7bae1577062376dcd37102348398fe04/NGCSiteCSS" type="text/css" rel="stylesheet"/>
<!--[if lt IE 9]>
<link href="/cassette.axd/stylesheet/2188ac5b8507764bb4079068f7a3c8d7ccfba0e7/ieCSS" type="text/css" rel="stylesheet"/>
<![endif]-->



    <script async type="text/javascript" id="_fed_an_ua_tag" src="https://web.archive.org/web/20180712201305js_/https://dap.digitalgov.gov/Universal­-Federated-­Analytics-­Min.js?agency=HHS&amp;subagency=AHRQ"></script>
    </head>
<body class="no-js content-page">
<a href="#main-content" id="skip-nav">Skip to main content</a>
<!--https://developers.google.com/tag-manager/devguide#multidomain  ECH-1199-->
    
    <!-- Google Tag Manager -->
    <noscript>
        <iframe src="//web.archive.org/web/20180712201305if_/https://www.googletagmanager.com/ns.html?id=GTM-W4NX5V" height="0" width="0" style="display:none;visibility:hidden"></iframe>
    </noscript>
    <script>
        (function (w, d, s, l, i) {
            w[l] = w[l] || []; w[l].push({
                'gtm.start':
                new Date().getTime(), event: 'gtm.js'
            }); var f = d.getElementsByTagName(s)[0],
            j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src =
            '//web.archive.org/web/20180712201305/https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f);
        })(window, document, 'script', 'dataLayer', 'GTM-W4NX5V');</script>

    <noscript>
        <iframe src="//web.archive.org/web/20180712201305if_/https://www.googletagmanager.com/ns.html?id=GTM-KHDP6Z" height="0" width="0" style="display:none;visibility:hidden"></iframe>
    </noscript>
    <script>
        (function (w, d, s, l, i) {
            w[l] = w[l] || []; w[l].push({
                'gtm.start':
                new Date().getTime(), event: 'gtm.js'
            }); var f = d.getElementsByTagName(s)[0],
            j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src =
            '//web.archive.org/web/20180712201305/https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f);
        })(window, document, 'script', 'dataLayer', 'GTM-KHDP6Z');</script>
    <!-- End Google Tag Manager -->


    <!-- AHRQ HEADER -->
<div id="ahrq-header">

	<p class="hhs-links">
		<a href="https://web.archive.org/web/20180712201305/http://www.hhs.gov/" target="_blank" class="logo-hhs"><span class="logomark"></span>U.S.&nbsp;Department of&nbsp;Health&nbsp;and Human&nbsp;Services</a>
		<a href="https://web.archive.org/web/20180712201305/http://www.hhs.gov/" target="_blank" class="external-link"><strong>HHS.gov</strong></a>
	</p><!-- /.hhs-links -->
	<p class="ahrq-links">
		<a href="https://web.archive.org/web/20180712201305/http://www.ahrq.gov/" target="_blank" class="logo-ahrq">Agency for Healthcare Research and Quality: Advancing Excellence in Health Care</a>
		<a href="https://web.archive.org/web/20180712201305/http://www.ahrq.gov/" target="_blank" class="external-link"><strong>AHRQ.gov</strong></a>
	</p><!-- /.ahrq-links -->

</div><!-- /#ahrq-header -->

	<!-- HEADER -->
	<div class="header" id="header">
		<div class="masthead">

			<ul class="header-actions">
				<li><a href="#header-search" class="search-action"><span class="label">Search</span></a></li>
				<li><a href="#header-account" class="account-action"><span class="label">Account</span></a></li>
				<li><a href="#main-nav" class="menu-action"><span class="label">Menu</span></a></li>
			</ul><!-- /.header-actions -->
				
				<a href="/web/20180712201305/https://www.guideline.gov/" class="header-logo NGC">
				    <picture>
				        <source media="(min-width: 960px)" srcset="/web/20180712201305im_/https://www.guideline.gov/UI/images/logo_NGC_header.png">
				        <source srcset="/web/20180712201305im_/https://www.guideline.gov/UI/images/logo_NGC_header_m.png">
				        <img src="/web/20180712201305im_/https://www.guideline.gov/UI/images/logo_NGC_header.png" alt="National Guideline Clearinghouse">
				    </picture>
				</a>
<form action="/web/20180712201305/https://www.guideline.gov/search" class="header-search header-action" enctype="multipart/form-data" id="header-search" method="get">					<p class="search-bar">
						<label for="q"><span class="screen-reader-text">Search</span>
							<input id="q" type="text" title="Search Input" name="q" class="search-input" placeholder="Search">
						</label>
						<input id="masthead-search-button" type="submit" title="Search Submit" class="search-submit" value="Search">
					</p>
					<p class="search-tips">
						<a href="/web/20180712201305/https://www.guideline.gov/help-and-about/search-browse/search-tips">Search Tips</a>
					</p>
</form>				<div class="header-account header-action" id="header-account">
				<a id="login-button" class="signin" href="/web/20180712201305/https://www.guideline.gov/accounts/signinlanding" aria-role="tab" aria-controls="login-panel" aria-selected="false">Log into My NGC</a>
<div id="login-panel" class="login dropdown" aria-role="tab-panel" aria-labeledby="login-button" aria-hidden="true">
    
            <div class="sign-in">
            <form id="sign-in-form" action="/web/20180712201305/https://www.guideline.gov/Accounts/LoginSubmit" method="post">
                <h3>Sign In</h3>
                <div class="errormessages"></div>
                <p class="invalid-user-cred message-block" style="display: none;"></p>
                <p>
                    <label for="sign-in-username">Username or Email <span class="required">*</span></label>
                    <input type="text" id="sign-in-username" class="input-text" name="email" required>
                   
                </p>
                <p>
                    <label for="sign-in-userpwd">Password <span class="required">*</span></label>
                    <input type="password" id="sign-in-userpwd" class="input-text" name="password" required>
                  
                </p>
                <p class="form-link"><a href="/web/20180712201305/https://www.guideline.gov/accounts/forgotpassword">Forgot Password?</a></p>
                <p><label for="remember-me"><input type="checkbox" name="remember-me" id="remember-me">Remember Me</label></p>
                <input id="account-sign-in" type="submit" value="Sign In"/>
            </form>
            <p>
                <label for="sign-up-btn">Don't have an account?</label>
                <a href="/web/20180712201305/https://www.guideline.gov/accounts/login" class="sign-up-btn" id="sign-up-btn">Create New Account</a>
            </p>
        </div><!--/.sign-in-->
</div><!-- /.login -->
				</div><!-- /.header-account -->
		</div><!-- /.masthead -->

		<div class="main-nav header-action" id="main-nav">
		    <ul class="level-1">
		        <li class=""><a href="/web/20180712201305/https://www.guideline.gov/">Home</a></li>
		        <li class=""><a href="/web/20180712201305/https://www.guideline.gov/new-this-week/index">New This Week</a></li>
		        <li>
<a href="/web/20180712201305/https://www.guideline.gov/summaries/browse" class="parent-link">Guideline Summaries</a>                    		            <ul class="level-2 dropdown">
                             <li class=""><a href="/web/20180712201305/https://www.guideline.gov/browse/clinical-specialty">By Clinical Specialty</a></li>
		                <li class=""><a href="/web/20180712201305/https://www.guideline.gov/browse/organization">By Organization</a></li>
		                <li class=""><a href="/web/20180712201305/https://www.guideline.gov/browse/mesh-tag">By MeSH Tag</a></li>
		                <li class=""><a href="/web/20180712201305/https://www.guideline.gov/summaries/in-progress">In Progress</a></li>
		                <li class=""><a href="/web/20180712201305/https://www.guideline.gov/summaries/archive">Archive</a></li>

		                <li class=""><a href="/web/20180712201305/https://www.guideline.gov/search?f_DocType=0&amp;fLockTerm=Guideline Summaries">All Summaries</a></li>
		            </ul>
		        </li>
<li class=""><a href="/web/20180712201305/https://www.guideline.gov/syntheses/index">Guideline Syntheses</a></li>		        <li class=""><a href="/web/20180712201305/https://www.guideline.gov/expert">Expert Commentaries</a></li>
		        <li class=""><a href="/web/20180712201305/https://www.guideline.gov/matrix">Matrix Tool</a></li>
		        <li class="">
<a href="/web/20180712201305/https://www.guideline.gov/summaries/submit">Submit Guidelines</a>                    		        </li>
                <li class=""><a href="/web/20180712201305/https://www.guideline.gov/help-and-about">Help &amp;&nbsp;About</a></li>		      
		    </ul>
		</div><!-- /.main-nav -->
</div><!-- /.header -->

    <br/><div class="content"><div class="fundingNotice2"><b>The AHRQ National Guideline Clearinghouse (NGC, guideline.gov) Web site will not be available after July 16, 2018</b> because federal funding <br/>through AHRQ will no longer be available to support the NGC as of that date. For additional information, read our <a href="/web/20180712201305/https://www.guideline.gov/home/announcements">full announcement</a>.</div></div>

	<!-- CONTENT -->
	<main id="main-content" tabindex="-1">
		

<div class="main">

		<div class="aside-container">

	<div class="content">

    <!-- CONTENT HEADER -->
    <div class="content-header">
        <ul class="content-header-meta">
            <li class="prefix-icon guideline">Guideline Summary</li>
            <li>NGC:010463</li>
            <li>2008 (revised 2014)
            </li>            
                                </ul>
        <div>
                <h1>ACR Appropriateness Criteria&reg; local excision in rectal cancer.</h1>
        </div>
    </div>
    <!-- /.content-header-meta -->

        <!-- CONTENT TABS -->
        <ul class="content-tabs">
            <li><a href="#developer-tab" class="developer is-active"><span class="label">Developer</span></a></li>
            <li><a href="#source-tab" class="source"><span class="label">Source</span></a></li>
            <li><a href="#status-tab" class="status"><span class="label">Status</span></a></li>
            <li><a href="#classification-tab" class="classification"><span class="label">Classification</span></a></li>
        </ul>
        <div id="developer-tab" class="is-active content-tab-panel">
                <ul class="developer-list">
        <li><a href="/web/20180712201305/https://www.guideline.gov/search?f_Guideline_Developer_String=American%20College%20of%20Radiology&amp;fLockTerm=American%2BCollege%2Bof%2BRadiology">American College of Radiology</a></li>
                        <li>   
                                <a id="246" href="#" data-alert="SignInLanding" data-alert-type="organization" class="get-alerts get-org-alerts">Get Alerts</a>
                        </li>
                </ul>
        </div>
    <!-- /.content-tab-panel -->
    <div id="source-tab" class="content-tab-panel">
<table><tr><td>Russo S, Blackstock AW, Herman JM, Abdel-Wahab M, Azad N, Das P, Goodman KA, Hong TS, Jabbour SK, Jones WE III, Konski AA, Koong AC, Kumar R, Rodriguez-Bigas M, Small W Jr, Thomas CR Jr, Suh WW, Expert Panel on Radiation Oncology-Gastrointestinal. ACR Appropriateness Criteria® local excision in rectal cancer [online publication]. Reston (VA): American College of Radiology (ACR); 2014. 10 p.  [69 references]</td></tr></table>                    <p><a href="/web/20180712201305/https://www.guideline.gov/Home/Disclaimer?id=48298&amp;contentType=fulltextlink&amp;redirect=https%253a%252f%252facsearch.acr.org%252fdocs%252f69500%252fNarrative%252f">View the original guideline documentation</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180712201305im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></p>
    </div>
    <!-- /.content-tab-panel -->
    <div id="status-tab" class="content-tab-panel">
            <p><div class="content_para"><p>This is the current release of the guideline.</p>
<p>This guideline updates a previous version: Blackstock AW, Russo SM, Konski AA, Suh WW, Cosman BC, Herman J, Mohiuddin M, Poggi MM, Regine WF, Saltz L, Small W Jr, Zook J, Expert Panel on Radiation Oncology-Rectal/Anal Cancer. ACR Appropriateness Criteria&reg; local excision in early-stage rectal cancer. [online publication]. Reston (VA): American College of Radiology (ACR); 2010. 5 p. [36 references]</p></div></p>
    </div>
    <!-- /.content-tab-panel -->
    <div id="classification-tab" class="content-tab-panel">


        
                            <h4>UMLS Concepts <a href="/web/20180712201305/https://www.guideline.gov/help-and-about/search-browse/umls-concepts" class="what-is">(what is this?)</a></h4>
                <div class="field">
                    <h5 class="field-label">ICD9CM</h5>
                    <div class="field-content">
<a href="/web/20180712201305/https://www.guideline.gov/search?f_ICD9CM_CUI=C0154062&amp;fLockTerm=Carcinoma+in+situ+of+rectum">Carcinoma in situ of rectum</a>
 (230.4), <a href="/web/20180712201305/https://www.guideline.gov/search?f_ICD9CM_CUI=C0949022&amp;fLockTerm=Malignant+neoplasm+of+rectum">Malignant neoplasm of rectum</a>
 (154.1)                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">MSH</h5>
                    <div class="field-content">
<a href="/web/20180712201305/https://www.guideline.gov/search?f_MSH_CUI=C0001418&amp;fLockTerm=Adenocarcinoma">Adenocarcinoma</a>
, <a href="/web/20180712201305/https://www.guideline.gov/search?f_MSH_CUI=C0436307&amp;fLockTerm=Chemoradiotherapy">Chemoradiotherapy</a>
, <a href="/web/20180712201305/https://www.guideline.gov/search?f_MSH_CUI=C0085533&amp;fLockTerm=Chemotherapy%2c+Adjuvant">Chemotherapy, Adjuvant</a>
, <a href="/web/20180712201305/https://www.guideline.gov/search?f_MSH_CUI=C0038898&amp;fLockTerm=Digestive+System+Surgical+Procedures">Digestive System Surgical Procedures</a>
, <a href="/web/20180712201305/https://www.guideline.gov/search?f_MSH_CUI=C0600558&amp;fLockTerm=Neoadjuvant+Therapy">Neoadjuvant Therapy</a>
, <a href="/web/20180712201305/https://www.guideline.gov/search?f_MSH_CUI=C0027643&amp;fLockTerm=Neoplasm+Recurrence%2c+Local">Neoplasm Recurrence, Local</a>
, <a href="/web/20180712201305/https://www.guideline.gov/search?f_MSH_CUI=C0034524&amp;fLockTerm=Radiation+Dosage">Radiation Dosage</a>
, <a href="/web/20180712201305/https://www.guideline.gov/search?f_MSH_CUI=C1522449&amp;fLockTerm=Radiotherapy">Radiotherapy</a>
, <a href="/web/20180712201305/https://www.guideline.gov/search?f_MSH_CUI=C0242939&amp;fLockTerm=Radiotherapy%2c+Adjuvant">Radiotherapy, Adjuvant</a>
, <a href="/web/20180712201305/https://www.guideline.gov/search?f_MSH_CUI=C0034885&amp;fLockTerm=Rectal+Neoplasms">Rectal Neoplasms</a>
                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">MTH</h5>
                    <div class="field-content">
<a href="/web/20180712201305/https://www.guideline.gov/search?f_MTH_CUI=C2004459&amp;fLockTerm=Abdominoperineal+resection">Abdominoperineal resection</a>
, <a href="/web/20180712201305/https://www.guideline.gov/search?f_MTH_CUI=C0001418&amp;fLockTerm=Adenocarcinoma">Adenocarcinoma</a>
, <a href="/web/20180712201305/https://www.guideline.gov/search?f_MTH_CUI=C0149978&amp;fLockTerm=Adenocarcinoma+of+rectum">Adenocarcinoma of rectum</a>
, <a href="/web/20180712201305/https://www.guideline.gov/search?f_MTH_CUI=C0154062&amp;fLockTerm=Carcinoma+in+situ+of+rectum">Carcinoma in situ of rectum</a>
, <a href="/web/20180712201305/https://www.guideline.gov/search?f_MTH_CUI=C0436307&amp;fLockTerm=Chemoradiotherapy">Chemoradiotherapy</a>
, <a href="/web/20180712201305/https://www.guideline.gov/search?f_MTH_CUI=C0949022&amp;fLockTerm=Malignant+Rectal+Neoplasm">Malignant Rectal Neoplasm</a>
, <a href="/web/20180712201305/https://www.guideline.gov/search?f_MTH_CUI=C0302617&amp;fLockTerm=Radiographic-therapeutic+unit+device">Radiographic-therapeutic unit device</a>
, <a href="/web/20180712201305/https://www.guideline.gov/search?f_MTH_CUI=C0278535&amp;fLockTerm=Rectal+cancer+stage+I">Rectal cancer stage I</a>
, <a href="/web/20180712201305/https://www.guideline.gov/search?f_MTH_CUI=C0007113&amp;fLockTerm=Rectal+Carcinoma">Rectal Carcinoma</a>
, <a href="/web/20180712201305/https://www.guideline.gov/search?f_MTH_CUI=C0034885&amp;fLockTerm=Rectal+Neoplasms">Rectal Neoplasms</a>
, <a href="/web/20180712201305/https://www.guideline.gov/search?f_MTH_CUI=C1522449&amp;fLockTerm=Therapeutic+radiology+procedure">Therapeutic radiology procedure</a>
                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">PDQ</h5>
                    <div class="field-content">
<a href="/web/20180712201305/https://www.guideline.gov/search?f_PDQ_CUI=C0149978&amp;fLockTerm=adenocarcinoma+of+the+rectum">adenocarcinoma of the rectum</a>
, <a href="/web/20180712201305/https://www.guideline.gov/search?f_PDQ_CUI=C0600558&amp;fLockTerm=neoadjuvant+therapy">neoadjuvant therapy</a>
, <a href="/web/20180712201305/https://www.guideline.gov/search?f_PDQ_CUI=C1522449&amp;fLockTerm=radiation+therapy">radiation therapy</a>
                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">SNOMEDCT_US</h5>
                    <div class="field-content">
<a href="/web/20180712201305/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C2004459&amp;fLockTerm=Abdominoperineal+resection">Abdominoperineal resection</a>
 (265414003), <a href="/web/20180712201305/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0001418&amp;fLockTerm=Adenocarcinoma">Adenocarcinoma</a>
 (35917007), <a href="/web/20180712201305/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0001418&amp;fLockTerm=Adenocarcinoma">Adenocarcinoma</a>
 (443961001), <a href="/web/20180712201305/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0149978&amp;fLockTerm=Adenocarcinoma+of+rectum">Adenocarcinoma of rectum</a>
 (254582000), <a href="/web/20180712201305/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0154062&amp;fLockTerm=Carcinoma+in+situ+of+rectum">Carcinoma in situ of rectum</a>
 (308879003), <a href="/web/20180712201305/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0154062&amp;fLockTerm=Carcinoma+in+situ+of+rectum">Carcinoma in situ of rectum</a>
 (92696009), <a href="/web/20180712201305/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0278259&amp;fLockTerm=Local+excision">Local excision</a>
 (86743009), <a href="/web/20180712201305/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0565292&amp;fLockTerm=Local+excision+of+rectum">Local excision of rectum</a>
 (287784004), <a href="/web/20180712201305/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C1282272&amp;fLockTerm=Low+anterior+resection+of+rectum">Low anterior resection of rectum</a>
 (314592008), <a href="/web/20180712201305/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0949022&amp;fLockTerm=Malignant+tumor+of+rectum">Malignant tumor of rectum</a>
 (363351006), <a href="/web/20180712201305/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0034885&amp;fLockTerm=Neoplasm+of+rectum">Neoplasm of rectum</a>
 (126847008), <a href="/web/20180712201305/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0038898&amp;fLockTerm=Operative+procedure+on+digestive+system">Operative procedure on digestive system</a>
 (107907001), <a href="/web/20180712201305/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C1522449&amp;fLockTerm=Radiation+oncology+AND%2fOR+radiotherapy">Radiation oncology AND/OR radiotherapy</a>
 (108290001), <a href="/web/20180712201305/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C1522449&amp;fLockTerm=Radiation+oncology+AND%2fOR+radiotherapy">Radiation oncology AND/OR radiotherapy</a>
 (53438000), <a href="/web/20180712201305/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0302617&amp;fLockTerm=Radiographic-therapeutic+unit">Radiographic-therapeutic unit</a>
 (10850003)                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">UMD</h5>
                    <div class="field-content">
<a href="/web/20180712201305/https://www.guideline.gov/search?f_UMD_CUI=C0302617&amp;fLockTerm=Radiotherapy+Systems">Radiotherapy Systems</a>
 (13-279)                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
    </div>
        <!-- /.content-tab-panel -->
        <!-- /.content-tab-panel -->
        <!-- TOOLBAR -->
        <div class="content-toolbar">

            <!-- Primary -->
            <ul class="tools primary-tools">
                <li class="dropdown tool sections">
                    <a href="#" class="tool-button">Sections</a>
                    <div class="dropdown-panel">
                            <ul class="section-links">
                                    <li><a href="#420" class="section-mark">Recommendations</a></li>
                                    <li><a href="#396" class="section-mark">Scope</a></li>
                                    <li><a href="#405" class="section-mark">Methodology</a></li>
                                    <li><a href="#424" class="section-mark">Evidence Supporting the Recommendations</a></li>
                                    <li><a href="#427" class="section-mark">Benefits/Harms of Implementing the Guideline Recommendations</a></li>
                                    <li><a href="#432" class="section-mark">Qualifying Statements</a></li>
                                    <li><a href="#434" class="section-mark">Implementation of the Guideline</a></li>
                                    <li><a href="#439" class="section-mark">Institute of Medicine (IOM) National Healthcare Quality Report Categories</a></li>
                                    <li><a href="#442" class="section-mark">Identifying Information and Availability</a></li>
                                    <li><a href="#99999" class="section-mark">Disclaimer</a></li>
                            </ul>    
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
            </ul>

            <!-- Other -->
            <ul class="tools other-tools">
                <li class="dropdown tool">
                    <a href="#" class="tool-button">Download</a>

                    <div class="dropdown-panel">
                        <ul>
                            <li><a href="/web/20180712201305/https://www.guideline.gov/summaries/downloadcontent/ngc-10463?contentType=pdf" class="pdf">.PDF 113.3 kb</a></li>
                            <li><a href="/web/20180712201305/https://www.guideline.gov/summaries/downloadcontent/ngc-10463?contentType=word" class="word">Word Document 320.4 kb</a></li>
                            <li><a href="/web/20180712201305/https://www.guideline.gov/summaries/downloadcontent/ngc-10463?contentType=xml" class="xml">.XML 67.2 kb</a></li>
                        </ul>
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
                <li class="dropdown tool">
                    <a href="#" class="tool-button">Share</a>
                    <div class="dropdown-panel">
                        <ul class="toolbar-social">
                            <li><a target="_blank" href="https://web.archive.org/web/20180712201305/https://www.facebook.com/sharer/sharer.php?u=https://www.guideline.gov/summaries/summary/48298/acr-appropriateness-criteria--local-excision-in-rectal-cancer" class="facebook">Facebook</a></li>
                            <li><a target="_blank" href="https://web.archive.org/web/20180712201305/https://twitter.com/share?text=&amp;url=https://www.guideline.gov/summaries/summary/48298/acr-appropriateness-criteria--local-excision-in-rectal-cancer" class="twitter">Twitter</a></li>
                            <li><a target="_blank" href="https://web.archive.org/web/20180712201305/https://www.linkedin.com/shareArticle?mini=true&amp;url=https://www.guideline.gov/summaries/summary/48298/acr-appropriateness-criteria--local-excision-in-rectal-cancer&amp;title=&amp;summary=&amp;source=" class="linkedin">Linkedin</a></li>
                            <li><a href="https://web.archive.org/web/20180712201305/mailto:/?Subject=AHRQ: ACR Appropriateness Criteria&amp;amp;reg; local excision in rectal cancer.&amp;body=https://www.guideline.gov/summaries/summary/48298/acr-appropriateness-criteria--local-excision-in-rectal-cancer" class="email">Email</a></li>
                        </ul>
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
                <li class="dropdown tool">
                    <a href="#" class="tool-button">Cite</a>
                    <div class="dropdown-panel citation">
                        <p class="text-label"><label for="citation">Citation: </label></p>
                        <textarea id="citation">National Guideline Clearinghouse (NGC). Guideline summary: ACR Appropriateness Criteria&reg; local excision in rectal cancer. In: National Guideline Clearinghouse (NGC) [Web site]. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ); 2014 Jan 01. [cited 2018 Jul 12]. Available: https://www.guideline.gov</textarea>                        
                        <p class="text-label">Download citation file: </p>
                        <ul>
                            <li><a href="/web/20180712201305/https://www.guideline.gov/summaries/citedownload/48298?format=ris">RIS (Zotero)</a></li>
                            <li><a href="/web/20180712201305/https://www.guideline.gov/summaries/citedownload/48298?format=enw">EndNote</a></li>
                            <li><a href="/web/20180712201305/https://www.guideline.gov/summaries/citedownload/48298?format=bibtex">BibTex</a></li>
                            <li><a href="/web/20180712201305/https://www.guideline.gov/summaries/citedownload/48298?format=txt">Medlars</a></li>
                            <li><a href="/web/20180712201305/https://www.guideline.gov/summaries/citedownload/48298?format=ris">ProCite</a></li>
                            <li><a href="/web/20180712201305/https://www.guideline.gov/summaries/citedownload/48298">RefWorks</a></li>
                            <li><a href="/web/20180712201305/https://www.guideline.gov/summaries/citedownload/48298?format=ris">Reference Manager</a></li>
                        </ul>
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
                                
                <li class="tool">
                        <a href="#" id="48298" data-alert="SignInLanding" class="tool-button save-link">Save</a>
                </li>
            </ul>

            <!-- Accordion -->
            <ul class="tools accordion-controls">
                <li class="tool"><a href="#" class="expand-all is-disabled" aria-disabled="true"><span class="screen-reader-text">Expand All</span></a></li>
                <li class="tool"><a href="#" class="collapse-all" aria-disabled="false"><span class="screen-reader-text">Collapse All</span></a></li>
            </ul>
        </div>
        <!-- /.toolbar -->


		<!-- ARTICLE -->
		<div class="article" id="article">
			




    <!-- ACCORDION -->
    <div class="accordion-container" role="tablist" multiselectable="true">
                <h2 id="420" class="accordion-title section-420 is-active" role="tab" aria-expanded="true"><a href="#">Recommendations</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Major Recommendations</a></h3>
                    <p><div class="content_para"><p><strong>ACR Appropriateness Criteria&reg;</strong></p>
<p><strong><span style="text-decoration: underline;">Clinical Condition</span>: Local Excision in Rectal Cancer</strong></p>
<p><strong><span style="text-decoration: underline;">Variant 1</span>: 57-year-old man with preoperative stage uT1N0, freely mobile, moderately differentiated adenocarcinoma. Tumor is 2 cm in diameter, involves &lt;25% circumference, and located 6 cm from anal verge. No lymphovascular space invasion is noted.</strong></p>
<table border="1" cellspacing="1" cellpadding="5" summary="Table: Variant 1: 57-year-old male with preoperative stage uT1N0, freely mobile, moderately differentiated adenocarcinoma. Tumor is 2 cm in diameter, involves less than 25% circumference, and located 6 cm from anal verge. No lymphovascular space invasion is noted">
    <thead>
        <tr>
            <th width="30%" class="Center" valign="bottom" scope="col">Treatment</th>
            <th width="20%" class="Center" valign="bottom" scope="col">Rating</th>
            <th width="50%" class="Center" valign="bottom" scope="col">Comments</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <th valign="top" colspan="3">Local Excision, pT1N0 and Negative Margins</th>
        </tr>
        <tr>
            <td valign="top">
            <p>Observation</p>
            </td>
            <td class="Center" valign="top">9</td>
            <td valign="top">&nbsp;</td>
        </tr>
        <tr>
            <td valign="top">
            <p>RT alone</p>
            </td>
            <td class="Center" valign="top">2</td>
            <td valign="top">&nbsp;</td>
        </tr>
        <tr>
            <td valign="top">
            <p>Chemoradiation</p>
            </td>
            <td class="Center" valign="top">1</td>
            <td valign="top">&nbsp;</td>
        </tr>
        <tr>
            <th valign="top" colspan="3">Local Excision, pT1N0 and Positive Margins</th>
        </tr>
        <tr>
            <td valign="top">
            <p>LAR or APR</p>
            </td>
            <td class="Center" valign="top">9</td>
            <td valign="top">&nbsp;</td>
        </tr>
        <tr>
            <td valign="top">
            <p>RT alone</p>
            </td>
            <td class="Center" valign="top">2</td>
            <td valign="top">&nbsp;</td>
        </tr>
        <tr>
            <td valign="top">
            <p>Chemoradiation</p>
            </td>
            <td class="Center" valign="top">2</td>
            <td valign="top">&nbsp;</td>
        </tr>
        <tr>
            <td valign="top">
            <p>Observation</p>
            </td>
            <td class="Center" valign="top">1</td>
            <td valign="top">&nbsp;</td>
        </tr>
    </tbody>
    <tfoot>
    <tr>
        <th valign="top" colspan="3"><span style="text-decoration: underline;">Rating Scale</span>: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate</th>
    </tr>
    </tfoot>
</table>
<p>Note: Abbreviations used in the tables are listed at the end of the "Major Recommendations" field.</p>
<p><strong>Discussion of Variant 1</strong></p>
<p>Patients with uT1N0 rectal cancers with negative margins and no clinical or histological factors associated with risk for local recurrence have excellent local control following local excision (LE) alone. Risk factors associated with increased risk for local recurrence include tumor size &gt;2.5 cm, adverse pathologic features (high-grade tumors and lymphovascular or perineural space invasion), or tumors occupying &gt;40% of the rectum.</p>
<p><strong><span style="text-decoration: underline;">Variant 2</span>: 65-year-old otherwise healthy woman with preoperative stage uT2N0 moderately differentiated adenocarcinoma. Tumor is 3 cm in diameter, freely mobile, and located 4 cm from anal verge. No lymphovascular space invasion is noted.</strong></p>
<table border="1" cellspacing="1" cellpadding="5" summary="Table: Variant 2: 65-year-old otherwise healthy female with preoperative stage uT2N0 moderately differentiated adenocarcinoma. Tumor is 3 cm in diameter, freely mobile, and located 4 cm from anal verge. No lymphovascular space invasion is noted">
    <thead>
        <tr>
            <th width="30%" class="Center" valign="bottom" scope="col">Treatment</th>
            <th width="20%" class="Center" valign="bottom" scope="col">Rating</th>
            <th width="50%" class="Center" valign="bottom" scope="col">Comments</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <th valign="top" colspan="3">Treatment Options </th>
        </tr>
        <tr>
            <td valign="top">
            <p>LAR or APR</p>
            </td>
            <td class="Center" valign="top">9</td>
            <td valign="top">&nbsp;</td>
        </tr>
        <tr>
            <td valign="top">
            <p>Local excision alone</p>
            </td>
            <td class="Center" valign="top">2</td>
            <td valign="top">&nbsp;</td>
        </tr>
        <tr>
            <td valign="top">
            <p>Local excision followed by adjuvant chemoradiation</p>
            </td>
            <td class="Center" valign="top">7</td>
            <td valign="top">Depending on pathologic features of local excision, definitive surgery with LAR or APR may still be indicated. </td>
        </tr>
        <tr>
            <td valign="top">
            <p>Neoadjuvant chemoradiation followed by local excision</p>
            </td>
            <td class="Center" valign="top">7</td>
            <td valign="top">For this treatment, consider surgical management following neoadjuvant chemoradiation based on response to therapy.</td>
        </tr>
        <tr>
            <td valign="top">
            <p>Local excision and radiation alone</p>
            </td>
            <td class="Center" valign="top">2</td>
            <td valign="top">&nbsp;</td>
        </tr>
        <tr>
            <th valign="top" colspan="3">If Local Excision with Chemoradiation: Radiation Dose to Primary<br/>
            </th>
        </tr>
        <tr>
            <td valign="top">
            <p>45 Gy/1.8 Gy</p>
            </td>
            <td class="Center" valign="top">7</td>
            <td valign="top">This treatment is a preoperative dose. Infusional 5-FU or capecitabine should be used daily.</td>
        </tr>
        <tr>
            <td valign="top">
            <p>50.4 Gy/1.8 Gy</p>
            </td>
            <td class="Center" valign="top">9</td>
            <td valign="top">This treatment is a preoperative dose. Infusional 5-FU or capecitabine should be used daily.</td>
        </tr>
        <tr>
            <td valign="top">
            <p>54 Gy/1.8 Gy</p>
            </td>
            <td class="Center" valign="top">7</td>
            <td valign="top">This treatment is a postoperative dose. Infusional 5-FU or capecitabine should be used daily unless small bowel is in radiation field.</td>
        </tr>
        <tr>
            <td valign="top">
            <p>59.4 Gy/1.8 Gy</p>
            </td>
            <td class="Center" valign="top">3</td>
            <td valign="top">This treatment is a postoperative dose. Infusional 5-FU or capecitabine should be used daily unless small bowel is in radiation field.</td>
        </tr>
        <tr>
            <th valign="top" colspan="3">Simulation</th>
        </tr>
        <tr>
            <td valign="top">
            <p>Patient prone</p>
            </td>
            <td class="Center" valign="top">9</td>
            <td valign="top">&nbsp;</td>
        </tr>
        <tr>
            <td valign="top">
            <p>Small-bowel contrast at simulation</p>
            </td>
            <td class="Center" valign="top">9</td>
            <td valign="top">&nbsp;</td>
        </tr>
        <tr>
            <td valign="top">
            <p>Patient immobilized</p>
            </td>
            <td class="Center" valign="top">9</td>
            <td valign="top">&nbsp;</td>
        </tr>
        <tr>
            <td valign="top">
            <p>Use belly board</p>
            </td>
            <td class="Center" valign="top">9</td>
            <td valign="top">Consider this if patient is prone.</td>
        </tr>
        <tr>
            <td valign="top">
            <p>Anal marker</p>
            </td>
            <td class="Center" valign="top">9</td>
            <td valign="top">&nbsp;</td>
        </tr>
        <tr>
            <td valign="top">
            <p>Bladder full at simulation</p>
            </td>
            <td class="Center" valign="top">7</td>
            <td valign="top">&nbsp;</td>
        </tr>
        <tr>
            <td valign="top">
            <p>Patient supine</p>
            </td>
            <td class="Center" valign="top">6</td>
            <td valign="top">This is usually appropriate with IMRT.</td>
        </tr>
        <tr>
            <th valign="top" colspan="3">If Local Excision with Chemoradiation: Radiation Volume</th>
        </tr>
        <tr>
            <td valign="top">
            <p>L5/S1 pelvis to bottom of ischial tuberosity with GTV determined using CT/MRI based treatment to 2&ndash;3 cm below tumor</p>
            </td>
            <td class="Center" valign="top">9</td>
            <td valign="top">&nbsp;</td>
        </tr>
        <tr>
            <th valign="top" colspan="3">Radiation Technique</th>
        </tr>
        <tr>
            <td valign="top">
            <p>IMRT</p>
            </td>
            <td class="Center" valign="top">6</td>
            <td valign="top">&nbsp;</td>
        </tr>
        <tr>
            <td valign="top">
            <p>3 field with photons</p>
            </td>
            <td class="Center" valign="top">9</td>
            <td valign="top">&nbsp;</td>
        </tr>
        <tr>
            <td valign="top">
            <p>4 field with photons</p>
            </td>
            <td class="Center" valign="top">9</td>
            <td valign="top">&nbsp;</td>
        </tr>
        <tr>
            <td valign="top">
            <p>AP/PA</p>
            </td>
            <td class="Center" valign="top">1</td>
            <td valign="top">&nbsp;</td>
        </tr>
    </tbody>
    <tfoot>
    <tr>
        <th valign="top" colspan="3"><span style="text-decoration: underline;">Rating Scale</span>: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate</th>
    </tr>
    </tfoot>
</table>
<p>Note: Abbreviations used in the tables are listed at the end of the "Major Recommendations" field.</p>
<p><strong>Discussion of Variant 2</strong></p>
<p>Patients with uT2N0 rectal cancers may be less reliably staged with endorectal ultrasound (EUS), indicating a higher risk for subclinical nodal involvement and risk for recurrence. In addition, larger tumor size may increase risk for local recurrence even if margins are uninvolved and no other adverse features are identified on final pathology. The addition of pelvic radiation with or without chemotherapy may reduce the risk of local recurrence. Furthermore, neoadjuvant therapy should be considered for uT2N0 patients.</p>
<p><strong><span style="text-decoration: underline;">Variant 3</span>: 60-year-old woman with uT3Nx adenocarcinoma located 4 cm from anal verge.</strong></p>
<table border="1" cellspacing="1" cellpadding="5" summary="Table: Variant 3: 60-year-old female with uT3Nx adenocarcinoma, located 4 cm from anal verge">
    <thead>
        <tr>
            <th width="30%" class="Center" valign="bottom" scope="col">Treatment</th>
            <th width="20%" class="Center" valign="bottom" scope="col">Rating</th>
            <th width="50%" class="Center" valign="bottom" scope="col">Comments</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td valign="top">Neoadjuvant chemoradiation followed by LAR or APR</td>
            <td class="Center" valign="top">9</td>
            <td valign="top">Refer to the National Guideline Clearinghouse (NGC) summary <a href="/web/20180712201305/https://www.guideline.gov/content.aspx?id=37913" title="Guideline #9218">ACR Appropriateness Criteria&reg; resectable rectal cancer</a>.</td>
        </tr>
        <tr>
            <td valign="top">Neoadjuvant chemoradiation followed by local excision</td>
            <td class="Center" valign="top">3</td>
            <td valign="top">This treatment may be appropriate for patients who are not eligible for LAR or APR because of medical reasons. </td>
        </tr>
        <tr>
            <td valign="top">Local excision alone</td>
            <td class="Center" valign="top">1</td>
            <td valign="top">&nbsp;</td>
        </tr>
    </tbody>
    <tfoot>
    <tr>
        <th valign="top" colspan="3"><span style="text-decoration: underline;">Rating Scale</span>: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate</th>
    </tr>
    </tfoot>
</table>
<p>Note: Abbreviations used in the tables are listed at the end of the "Major Recommendations" field.</p>
<p><strong>Discussion of Variant 3</strong></p>
<p>Although there are some single-institution studies that suggest some uT3N0 rectal cancers may be treated with neoadjuvant chemoradiation followed by LE if a good tumor response is demonstrated on restaging studies, the standard of care for T3 lesions remains low anterior resection (LAR) or abdominoperineal resection (APR) following neoadjuvant therapy, and the use of LE should be considered only in the setting of clinical trial or for those patients with severe comorbidities limiting surgery.</p>
<p><strong><span style="text-decoration: underline;">Summary of Literature Review</span></strong></p>
<p><strong>Introduction/Background</strong></p>
<p>Thirty-nine percent of patients diagnosed with rectal cancer present with what the American Joint Commission on Cancer (AJCC) considers stage I disease. Historically these patients have been treated with LAR or APR with excellent local control and survival rates. Postulating that early-stage lesions may not warrant such aggressive treatment as well as acknowledging the mortality and morbidity of these procedures, investigators have examined less morbid sphincter-sparing approaches such as LE. In addition, LE has been presented as an option to patients whose other comorbid conditions would not allow them to tolerate more extensive surgery. In recent years there has been additional evidence supporting the use of LE. There has been growing interest in the use of neoadjuvant radiation therapy (RT) or chemoradiation therapy to improve outcome for patients with T1 or T2 cancers undergoing LE. The interest in the use of neoadjuvant RT or chemoradiation therapy is also in extending the indications for less radical surgery to selected patients with early-stage cancers at increased risk for local recurrence or patients with severe comorbidities and T3 cancers who have a complete or near-complete response to preoperative therapy. A few prospective multi-institutional trials have investigated the efficacy of LE RT or chemoradiation therapy in these patients.</p>
<p><strong>Workup</strong></p>
<p>All patients should receive a full colonoscopy with biopsy, pathology review, proctoscopy, carcinoembryonic antigen, and computerized tomography (CT) of the chest, abdomen, and pelvis. Since depth of tumor invasion has been shown to be an independent predictor for lymph node metastases in rectal cancer, patients being considered for LE should have an EUS to evaluate depth of penetration. EUS is 62% to 92% accurate for T staging and 64% to 88% accurate for N staging but is highly operator dependent. However, EUS may be more accurate for staging T1 and T3 rectal tumors and less accurate for tumors, indicating the need for incorporation of other modalities in the workup of patients who are being considered for LE. Magnetic resonance imaging (MRI) is more commonly included in the staging workup for patients with rectal cancer. High spatial resolution MRI of the pelvis provides more detailed anatomical information for locoregional staging, especially when the information to be gained may impact local treatment recommendations. The prognostic value of preoperative high-resolution MRI assessment was evaluated in 374 patients with rectal cancer, demonstrating the superiority of MRI to AJCC TNM-based criteria in predicting risk of circumferential resection margin and assessing risk of local recurrence (LR), disease-free survival, and overall survival, as circumferential resection margin involvement is significantly associated with increased risk of distant metastatic disease.</p>
<p><strong>Surgical Technique</strong></p>
<p>There are three operative approaches for LE of a distal rectal lesion: transanal, posterior trans-sphincteric (York-Mason procedure), or posterior proctotomy (Kraske procedure). Transanal excision is the most commonly used approach. Under direct visualization, the lesion is excised with a 1 cm margin including the perirectal fat. The mural defect is then closed. The posterior trans-sphincteric and posterior proctotomy approaches are used less commonly and involve posterior approaches with dissection above or below the levator ani to the rectum. It is important to note that none of these procedures includes lymph node evaluation. Transanal endoscopic microsurgery (TEM) allows locally complete excision of rectal neoplasms and has recently been evaluated for curative treatment of invasive cancer. TEM has been shown to be as effective and associated with less morbidity than conventional transanal excision, and is safe following chemoradiation therapy. In fact, retrospective data suggest that LE or TEM used with or without neoadjuvant chemoradiation therapy in carefully selected patients staged with EUS and MRI demonstrate long-term control compared to data reported in the literature for patients treated with total mesorectal excision (TME).</p>
<p><strong>Patient Selection</strong></p>
<p>Historically, the best candidates for LE include small (&lt;4 cm), low-lying tumors confined to the muscularis propria (See Variant 1 above.) Patients with adverse pathologic features (mucinous/signet ring histology, poor differentiation, lymphovascular space invasion) or whose tumors occupy more than 40% of the rectum are at high risk for local recurrence, and LE is not recommended. These patients should be offered radical surgery. Patients with positive margins after LE or piecemeal resections are at very high risk of local recurrence and should be offered immediate radical surgery. In general, patients with T2 tumors have a sufficiently high risk of lymph node involvement to warrant consideration of neoadjuvant therapy if radical surgery is not performed (See Variant 2 above.) Patients with tumors invading the muscularis propria (T3) are at very high risk (&gt;30%) for local recurrence following LE and should not be treated with LE alone but may be considered for neoadjuvant therapy followed by restaging and consideration of LE for nonsurgical candidates with complete or near complete tumor response. Radical surgery following chemoradiotherapy is considered standard of care for patients with T3 tumors able to undergo surgery, and neoadjuvant chemoradiation therapy followed by LE should be considered only in a clinical trial setting. Palliative LE may otherwise be performed in advanced-stage patients.</p>
<p><strong>Local Excision with or without Radiation Therapy</strong></p>
<p>Single-institution reviews have reported failure rates of 7% to 40% and 25% to 62% for LE alone in T1 and T2 tumors, respectively. Postoperative RT may lower these rates to 10% to 20% and there are increasing data to suggest the role of prognostic factors to select patients who are at risk for recurrence and may benefit from adjuvant treatment. Tumor diameter, pathologic T stage and extent of submucosal spread, high tumor grade, positive surgical margin, and perineural or lymphovascular invasion have been identified as independent predictors of recurrence following LE. Hence, patient and/or tumor specific characteristics may influence recommendations for adjuvant therapy and may be incorporated into algorithms proposed for the selection of patients to be treated with LE alone.</p>
<p>In addition, patients with subclinical nodal metastases undergoing LE alone are at risk for recurrence. Female sex, age, upper tumor location, pathological features (high tumor grade, lymphovascular or perineural invasion, extensive submucosal spread), and deep invasion have been shown to be independent predictors for lymph node metastases and may be useful in identifying patients who would benefit from adjuvant therapy in addition to LE. However, restaging of patients being considered for LE following neoadjuvant therapy can be even more challenging using standard staging techniques. One prospective multicenter study demonstrated that restaging MRI using lymph node-specific contrast interpreted by an experienced radiologist can select rectal cancer with low risk of undetected nodal metastases (negative predictive value = 0.9) following neoadjuvant chemoradiation therapy and may be useful in identifying candidates for LE. Other investigators have demonstrated that MRI can detect reductions in tumor volume following neoadjuvant therapy and that a &gt;75% tumor volume reduction ratio is significantly associated with a high pathologic complete response rate, which may identify patients who are candidates for LE following neoadjuvant chemoradiation therapy. However, when considering LE following neoadjuvant chemoradiation therapy, evaluation of primary tumor response should be taken with caution as demonstrated in a retrospective study of 725 patients for which the incidence of lymph node metastases was 9.7% for ypT0 and 17.6% for ypT1 following neoadjuvant chemoradiation therapy and radical surgery. To date, the best way to evaluate lymph nodes in the mesorectum following neoadjuvant therapy has not been clearly defined. The use of MRI to assess tumor response following chemoradiotherapy demonstrates promise in defining candidates for LE following neoadjuvant therapy.</p>
<p>An initial phase II study by the Radiation Oncology Therapy Group&reg; (RTOG&reg; 89-02) assigned patients to observation (low-grade T1 tumors with negative margins) or chemoradiation (54-65 Gy with 5-fluorouracil [5-FU] 1,000 mg/m<sup>2</sup> intravenously [IV] days 1‒3, days 29-31) based on postexcision pathology. Local recurrence rates were 7%, 8%, and 23% for T1, T2, and T3 tumors, respectively. Cancer and Leukemia Group B study (CALGB 8984) evaluated the role of LE with or without chemotherapy and RT in 177 patients with T1 and T2 adenocarcinomas of the rectum. T1 patients underwent LE followed by observation. T2 patients underwent LE followed by RT (54 Gy/30 fractions) and chemotherapy (5-FU 500 mg/m<sup>2</sup> IV days 1‒3, days 29‒31). At 48 months of median follow-up, the 6-year overall survival rate was 85% and the disease-free survival rate was 78% for all patients. Three of the 59 eligible T1 patients and seven of the 51 eligible T2 patients had experienced local failure. It is important to note, however, that these were highly selected patients and one-third of patients were excluded after surgery due to large tumor size and/or questionable margin status (See Variant 3 above.)</p>
<p>More recently, LE or TEM following neoadjuvant radiation with or without chemotherapy has been reported. Data from retrospective studies and two prospective studies have demonstrated safety and local control (LC) rates ranging from 2.0% to 13.2%. In one of these studies, a multi-institutional phase II trial was conducted by the American College of Surgeons Oncology Group (ACOSOG Z6041) investigating neoadjuvant chemoradiation therapy utilizing capecitabine and oxaliplatin followed by LE in T2 patients. Forty-four percent of patients achieved a pathologic complete response, and 64% of tumors were downstaged to ypT0-1. Approximately 5% of patients were found to have ypT3 tumors at the time of LE. All but one patient had negative margins. The therapy was associated with 39% of patients developing grade &ge;3 treatment-related complications. The study demonstrated that chemoradiation therapy followed by LE for clinically staged T2N0 tumors results in a high pathologic complete response rate and negative resection margins but a high complication rate.</p>
<p><strong>Simulation and Treatment Technique</strong></p>
<p>Patients treated with three-dimensional (3-D) conformal RT can be physically positioned at the time of simulation to displace the small bowel in order to minimize treatment toxicity, and small-bowel contrast can be used to assist in identification of small bowel for treatment planning purposes. The use of a belly board with the patient in prone position with a full bladder has been shown to reduce the volume of irradiated small bowel by approximately 70% (about 100 cc). However, this position may be difficult for some patients to tolerate. Another prospective study comparing treatment in the prone versus supine position demonstrated a primarily low-dose region of the dose-volume histogram for the small-bowel associated with the prone position, although there was no appreciable difference between supine and prone positioning in the volume of small bowel receiving higher doses (&gt;20 Gy).</p>
<p>Alternatively, patients may be treated with intensity-modulated radiation therapy (IMRT) using a supine positioning. The dose-sculpting capabilities of IMRT reduce the need to displace bowel away from the treatment volume and potentially obviate the benefit derived from placing the patient in the prone position on a belly board. Retrospective comparison of treatment in the prone versus supine position, with or without daily image guidance, demonstrates that prone positioning leads to a greater systematic error, whereas the supine position was associated with increased random error. However, the increased use of image guidance was noted to decrease the setup error associated with supine positioning.</p>
<p>Hence, 3-field or 4-field 3-D conformal treatment technique with prone setup using a belly board with or without full bladder to displace bowel from radiation field is an acceptable method of treatment. Likewise, 3-field or 4-field 3-D conformal radiation using a supine technique with frequent image guidance, as well as IMRT optimization using small-bowel dose constraints are also acceptable methods of treatment.</p>
<p><strong>Future Directions</strong></p>
<p>No studies to date have prospectively evaluated whether or not the use of neoadjuvant therapy reduces recurrence rates compared to LE or TEM alone. Future studies are designed to further evaluate the efficacy and safety of TEM following neoadjuvant chemoradiation therapy for rectal cancer patients at a higher risk for local recurrence. The CARTS-study (NCT01273051) is a multicenter feasibility study investigating the role of rectum-saving surgery for patients with clinical T1-3 distal rectal adenocarcinoma below 10 cm from the anal verge. In this study patients will receive neoadjuvant chemoradiation therapy (25 fractions of 2 Gy with concurrent capecitabine) followed by TEM 8 to 10 weeks after the end of the preoperative therapy depending on the clinical response. The primary objective is to determine the number of patients with complete pathological response after chemoradiation therapy, and secondary endpoints will examine local recurrence rate and quality of life. In addition, several other international trials will formally address the role of LE in rectal cancer. The French multicenter Groupe de Recherche Chirurgicale sur le Cancer du Rectum (GRECCAR) 2 trial (NCT00427375) will enroll patients with rectal tumors &le;4 cm to receive neoadjuvant chemoradiation therapy followed by reevaluation at 6 to 8 weeks. Patients with tumors &le;2 cm will then undergo either LE or TME. A randomized Polish multicenter trial (NCT00738790) for patients with cT1-3, N0 rectal cancer will compare short course RT (5 &times; 5 Gy with a 4 Gy boost after 1 week) to standard fractionation chemoradiation therapy followed by LE performed 6 weeks after completion of neoadjuvant therapy. Finally, the Spanish trial (NCT01308190) will randomize TME with chemoradiation therapy followed by LE in patients with clinically staged T2 or superficial T3 low rectal cancer. The expert panel awaits the results of these randomized trials to help better define the role of LE following neoadjuvant therapy in selected patients.</p>
<p><strong>Summary</strong></p>
<ul style="list-style-type: disc;">
    <li>TEM is emerging as an option for LE and is associated with low morbidity rates compared to other techniques. </li>
    <li>LE alone may be an acceptable treatment strategy for uT1N0 rectal cancers without high-risk features associated with increased risk of recurrence. </li>
    <li>Patients who undergo LE for early-stage rectal cancers and have known clinical or pathological adverse risk factors may benefit from adjuvant radiation or chemoradiation therapy. </li>
    <li>Patients with uT2N0 rectal cancers may be understaged by EUS and are associated with a higher risk of lymph node metastases. Adjuvant or neoadjuvant therapy should be considered in these patients. </li>
    <li>Although there are some single institution studies that suggest some uT3N0 rectal cancers may be treated with neoadjuvant chemoradiation followed by LE if a complete or near-complete tumor response is demonstrated on restaging studies, most of the patients who were included in these analyses were not surgical candidates. The standard of care for T3 lesions remains LAR or APR following neoadjuvant therapy, and the use of LE should be considered only in the setting of clinical trial or for those patients with severe comorbidities limiting surgery. The expert panel awaits the results of several randomized trials to better define the role of LE following neoadjuvant therapy for these higher risk patients. </li>
</ul>
<p><strong>Abbreviations</strong></p>
<ul style="list-style-type: disc;">
    <li>5-FU, 5-fluorouracil </li>
    <li>AP/PA, anterior-posterior/posterior-anterior </li>
    <li>APR, abdominoperineal resection </li>
    <li>CT, computed tomography </li>
    <li>GTV, gross tumor volume </li>
    <li>IMRT,&nbsp; intensity-modulated radiation therapy </li>
    <li>LAR, low anterior resection </li>
    <li>MRI, magnetic resonance imaging </li>
    <li>RT, radiation therapy </li>
</ul></div></p>
                        <h3><a href="#">Clinical Algorithm(s)</a></h3>
                    <p><div class="content_para"><p>Algorithms were not developed from criteria guidelines.</p></div></p>

            </div>
                <h2 id="396" class="accordion-title section-396 is-active" role="tab" aria-expanded="true"><a href="#">Scope</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Disease/Condition(s)</a></h3>
                    <p><div class="content_para"><p>Rectal cancer</p></div></p>
                        <h3><a href="#">Guideline Category</a></h3>
                    <p>Evaluation</p>
                    <p>Treatment</p>
                        <h3><a href="#">Clinical Specialty</a></h3>
                    <p>Colon and Rectal Surgery</p>
                    <p>Gastroenterology</p>
                    <p>Internal Medicine</p>
                    <p>Oncology</p>
                    <p>Radiation Oncology</p>
                    <p>Radiology</p>
                        <h3><a href="#">Intended Users</a></h3>
                    <p>Health Plans</p>
                    <p>Hospitals</p>
                    <p>Managed Care Organizations</p>
                    <p>Physicians</p>
                    <p>Utilization Management</p>
                        <h3><a href="#">Guideline Objective(s)</a></h3>
                    <p><div class="content_para"><p>To evaluate the appropriateness of local excision with or without chemoradiation therapy for patients with rectal cancer</p></div></p>
                        <h3><a href="#">Target Population</a></h3>
                    <p><div class="content_para"><p>Patients with rectal cancer</p></div></p>
                        <h3><a href="#">Interventions and Practices Considered</a></h3>
                    <p><ol style="list-style-type: decimal;">
    <li>Abdominoperineal resection (APR) </li>
    <li>Low anterior resection (LAR) </li>
    <li>Local excision alone </li>
    <li>Local excision followed by
    <ul style="list-style-type: disc;">
        <li>Radiation therapy (RT) alone </li>
        <li>Adjuvant chemoradiation </li>
        <li>Observation </li>
        <li>LAR or APR </li>
    </ul>
    </li>
    <li>Neoadjuvant chemoradiation followed by:
    <ul style="list-style-type: disc;">
        <li>Local excision </li>
        <li>LAR or APR </li>
    </ul>
    </li>
    <li>Consideration of radiation dose </li>
    <li>Consideration of radiation volume </li>
    <li>Consideration of radiation technique
    <ul style="list-style-type: disc;">
        <li>3 or 4 field with photons </li>
        <li>Anterior-posterior/posterior-anterior (AP/PA) </li>
        <li>Intensity-modulated radiation therapy (IMRT) </li>
    </ul>
    </li>
    <li>Simulation
    <ul style="list-style-type: disc;">
        <li>Patient prone </li>
        <li>Small-bowel contrast at simulation </li>
        <li>Patient immobilized </li>
        <li>Use of belly board </li>
        <li>Anal marker </li>
        <li>Bladder full at simulation </li>
        <li>Patient supine </li>
    </ul>
    </li>
</ol></p>
                        <h3><a href="#">Major Outcomes Considered</a></h3>
                    <p><ul style="list-style-type: disc;">
    <li>Failure rate</li>
    <li>Local recurrence rate</li>
    <li>Disease-free and overall survival rates</li>
    <li>Pathologic complete response </li>
</ul></p>

            </div>
                <h2 id="405" class="accordion-title section-405 is-active" role="tab" aria-expanded="true"><a href="#">Methodology</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Methods Used to Collect/Select the Evidence</a></h3>
                    <p>Searches of Electronic Databases</p>
                        <h3><a href="#">Description of Methods Used to Collect/Select the Evidence</a></h3>
                    <p><div class="content_para"><p><strong>Literature Search Procedure</strong></p>
<p>Staff search in PubMed only for peer reviewed medical literature for routine searches. Any article or guideline may be used by the author in the narrative but those materials may have been identified outside of the routine literature search process.</p>
<p>The Medline literature search is based on keywords provided by the topic author. The two general classes of keywords are those related to the condition (e.g., ankle pain, fever) and those that describe the diagnostic or therapeutic intervention of interest (e.g., mammography, MRI).</p>
<p>The search terms and parameters are manipulated to produce the most relevant, current evidence to address the American College of Radiology Appropriateness Criteria (ACR AC) topic being reviewed or developed. Combining the clinical conditions and diagnostic modalities or therapeutic procedures narrows the search to be relevant to the topic. Exploding the term "diagnostic imaging" captures relevant results for diagnostic topics.</p>
<p>The following criteria/limits are used in the searches.</p>
<ol style="list-style-type: decimal;">
    <li>Articles that have abstracts available and are concerned with humans. </li>
    <li>Restrict the search to the year prior to the last topic update or in some cases the author of the topic may specify which year range to use in the search. For new topics, the year range is restricted to the last 10 years unless the topic author provides other instructions. </li>
    <li>May restrict the search to Adults only or Pediatrics only. </li>
    <li>Articles consisting of only summaries or case reports are often excluded from final results. </li>
</ol>
<p>The search strategy may be revised to improve the output as needed.</p></div></p>
                        <h3><a href="#">Number of Source Documents</a></h3>
                    <p><div class="content_para"><p>The total number of source documents identified as the result of the literature search is not known.</p></div></p>
                        <h3><a href="#">Methods Used to Assess the Quality and Strength of the Evidence</a></h3>
                    <p>Weighting According to a Rating Scheme (Scheme Given)</p>
                        <h3><a href="#">Rating Scheme for the Strength of the Evidence</a></h3>
                    <p><div class="content_para"><p><strong>Study Quality Category Definitions</strong></p>
<p>Category 1 - The study is well-designed and accounts for common biases.</p>
<p>Category 2 - The study is moderately well-designed and accounts for most common biases.</p>
<p>Category 3 - There are important study design limitations.</p>
<p>Category 4 - The study is not useful as primary evidence. The article may not be a clinical study or the study design is invalid, or conclusions are based on expert consensus. For example:</p>
<ol style="list-style-type: lower-alpha;">
    <li>The study does not meet the criteria for or is not a hypothesis-based clinical study (e.g., a book chapter or case report or case series description). </li>
    <li>The study may synthesize and draw conclusions about several studies such as a literature review article or book chapter but is not primary evidence. </li>
    <li>The study is an expert opinion or consensus document. </li>
</ol></div></p>
                        <h3><a href="#">Methods Used to Analyze the Evidence</a></h3>
                    <p>Systematic Review with Evidence Tables</p>
                        <h3><a href="#">Description of the Methods Used to Analyze the Evidence</a></h3>
                    <p><div class="content_para"><p>The topic author drafts or revises the narrative text summarizing the evidence found in the literature. American College of Radiology (ACR) staff draft an evidence table based on the analysis of the selected literature. These tables rate the strength of the evidence (study quality) for each article included in the narrative text.</p>
<p>The expert panel reviews the narrative text, evidence table, and the supporting literature for each of the topic-variant combinations and assigns an appropriateness rating for each procedure listed in the table. Each individual panel member assigns a rating based on his/her interpretation of the available evidence.</p>
<p>More information about the evidence table development process can be found in the ACR Appropriateness Criteria&reg; Evidence Table Development document (see the "Availability of Companion Documents" field).</p></div></p>
                        <h3><a href="#">Methods Used to Formulate the Recommendations</a></h3>
                    <p>Expert Consensus (Delphi)</p>
                        <h3><a href="#">Description of Methods Used to Formulate the Recommendations</a></h3>
                    <p><div class="content_para"><p><strong>Rating Appropriateness</strong></p>
<p>The appropriateness ratings for each of the procedures included in the Appropriateness Criteria topics are determined using a modified Delphi methodology. A series of surveys are conducted to elicit each panelist's expert interpretation of the evidence, based on the available data, regarding the appropriateness of an imaging or therapeutic procedure for a specific clinical scenario. American College of Radiology (ACR) staff distribute surveys to the panelists along with the evidence table and narrative. Each panelist interprets the available evidence and rates each procedure. The surveys are completed by panelists without consulting other panelists. The appropriateness rating scale is an ordinal scale that uses integers from 1 to 9 grouped into three categories: 1, 2, or 3 are in the category "usually not appropriate"; 4, 5, or 6 are in the category "may be appropriate"; and 7, 8, or 9 are in the category "usually appropriate." Each panel member assigns one rating for each procedure for a clinical scenario. The ratings assigned by each panel member are presented in a table displaying the frequency distribution of the ratings without identifying which members provided any particular rating.</p>
<p>If consensus is reached, the median rating is assigned as the panel's final recommendation/rating. Consensus is defined as eighty percent (80%) agreement within a rating category. A maximum of three rounds may be conducted to reach consensus. Consensus among the panel members must be achieved to determine the final rating for each procedure.</p>
<p>If consensus is not reached, the panel is convened by conference call. The strengths and weaknesses of each imaging procedure that has not reached consensus are discussed and a final rating is proposed. If the panelists on the call agree, the rating is proposed as the panel's consensus. The document is circulated to all the panelists to make the final determination. If consensus cannot be reached on the call or when the document is circulated, "No consensus" appears in the rating column and the reasons for this decision are added to the comment sections.</p>
<p>This modified Delphi method enables each panelist to express individual interpretations of the evidence and his or her expert opinion without excessive influence from fellow panelists in a simple, standardized and economical process. A more detailed explanation of the complete process can be found in additional methodology documents found on the <a href="/web/20180712201305/https://www.guideline.gov/Home/Disclaimer?id=48298&amp;contentType=summary&amp;redirect=http%3a%2f%2fwww.acr.org%2fac" title="ACR Web site">ACR Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180712201305im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/> (see also the "Availability of Companion Documents" field).</p></div></p>
                        <h3><a href="#">Rating Scheme for the Strength of the Recommendations</a></h3>
                    <p><div class="content_para"><p>Not applicable</p></div></p>
                        <h3><a href="#">Cost Analysis</a></h3>
                    <p><div class="content_para"><p>A formal cost analysis was not performed and published cost analyses were not reviewed.</p></div></p>
                        <h3><a href="#">Method of Guideline Validation</a></h3>
                    <p>Internal Peer Review</p>
                        <h3><a href="#">Description of Method of Guideline Validation</a></h3>
                    <p><div class="content_para"><p>Criteria developed by the Expert Panels are reviewed by the American College of Radiology (ACR) Committee on Appropriateness Criteria.</p></div></p>

            </div>
                <h2 id="424" class="accordion-title section-424 is-active" role="tab" aria-expanded="true"><a href="#">Evidence Supporting the Recommendations</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Type of Evidence Supporting the Recommendations</a></h3>
                    <p><div class="content_para"><p>The recommendations are based on analysis of the current literature and expert panel consensus.</p></div></p>

            </div>
                <h2 id="427" class="accordion-title section-427 is-active" role="tab" aria-expanded="true"><a href="#">Benefits/Harms of Implementing the Guideline Recommendations</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Potential Benefits</a></h3>
                    <p><div class="content_para"><p>Selection of appropriate treatment procedures for patients with rectal cancer</p></div></p>
                        <h3><a href="#">Potential Harms</a></h3>
                    <p><ul style="list-style-type: disc;">
    <li>The American College of Surgeons Oncology Group (ACSOG Z6041) investigated neoadjuvant chemoradiation utilizing capecitabine and oxaliplatin followed by local excision in T2 patients. The therapy was associated with 39% of patients developing grade &ge;3 treatment-related complications. </li>
    <li>Retrospective comparison of treatment in the prone versus supine position during intensity-modulated radiation therapy (IMRT), with or without daily image guidance, demonstrates that prone positioning leads to a greater systematic error, whereas the supine position was associated with increased random error. However, the increased use of image guidance was noted to decrease the setup error associated with supine positioning. </li>
</ul></p>

            </div>
                <h2 id="432" class="accordion-title section-432 is-active" role="tab" aria-expanded="true"><a href="#">Qualifying Statements</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Qualifying Statements</a></h3>
                    <p><div class="content_para"><p>The American College of Radiology (ACR) Committee on Appropriateness Criteria and its expert panels have developed criteria for determining appropriate imaging examinations for diagnosis and treatment of specified medical condition(s). These criteria are intended to guide radiologists, radiation oncologists, and referring physicians in making decisions regarding radiologic imaging and treatment. Generally, the complexity and severity of a patient's clinical condition should dictate the selection of appropriate imaging procedures or treatments. Only those examinations generally used for evaluation of the patient's condition are ranked. Other imaging studies necessary to evaluate other co-existent diseases or other medical consequences of this condition are not considered in this document. The availability of equipment or personnel may influence the selection of appropriate imaging procedures or treatments. Imaging techniques classified as investigational by the U.S. Food and Drug Administration (FDA) have not been considered in developing these criteria; however, study of new equipment and applications should be encouraged. The ultimate decision regarding the appropriateness of any specific radiologic examination or treatment must be made by the referring physician and radiologist in light of all the circumstances presented in an individual examination.</p></div></p>

            </div>
                <h2 id="434" class="accordion-title section-434 is-active" role="tab" aria-expanded="true"><a href="#">Implementation of the Guideline</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Description of Implementation Strategy</a></h3>
                    <p><div class="content_para"><p>An implementation strategy was not provided.</p></div></p>

            </div>
                <h2 id="439" class="accordion-title section-439 is-active" role="tab" aria-expanded="true"><a href="#">Institute of Medicine (IOM) National Healthcare Quality Report Categories</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">IOM Care Need</a></h3>
                    <p>Getting Better</p>
                    <p>Living with Illness</p>
                        <h3><a href="#">IOM Domain</a></h3>
                    <p>Effectiveness</p>

            </div>
                <h2 id="442" class="accordion-title section-442 is-active" role="tab" aria-expanded="true"><a href="#">Identifying Information and Availability</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Bibliographic Source(s)</a></h3>
                    <p><table><tr><td>Russo S, Blackstock AW, Herman JM, Abdel-Wahab M, Azad N, Das P, Goodman KA, Hong TS, Jabbour SK, Jones WE III, Konski AA, Koong AC, Kumar R, Rodriguez-Bigas M, Small W Jr, Thomas CR Jr, Suh WW, Expert Panel on Radiation Oncology-Gastrointestinal. ACR Appropriateness Criteria® local excision in rectal cancer [online publication]. Reston (VA): American College of Radiology (ACR); 2014. 10 p.  [69 references]</td></tr></table></p>
                        <h3><a href="#">Adaptation</a></h3>
                    <p><div class="content_para"><p>Not applicable: The guideline was not adapted from another source.</p></div></p>
                        <h3><a href="#">Date Released</a></h3>
                    <p>2008 (revised 2014)</p>
                        <h3><a href="#">Guideline Developer(s)</a></h3>
                    <p>American College of Radiology - Medical Specialty Society</p>
                        <h3><a href="#">Source(s) of Funding</a></h3>
                    <p><div class="content_para"><p>The American College of Radiology (ACR) provided the funding and the resources for these ACR Appropriateness Criteria&reg;.</p></div></p>
                        <h3><a href="#">Guideline Committee</a></h3>
                    <p><div class="content_para"><p>Committee on Appropriateness Criteria, Expert Panel on Radiation Oncology&ndash;Gastrointestinal</p></div></p>
                        <h3><a href="#">Composition of Group That Authored the Guideline</a></h3>
                    <p><div class="content_para"><p><em>Panel Members</em>: Suzanne Russo, MD (<em>Research Author</em>); A. William Blackstock, MD (<em>Principal Author</em>); Joseph M. Herman, MD, MSc (<em>Panel Vice-chair</em>); May Abdel-Wahab, MD, PhD; Nilofer Azad, MD; Prajnan Das, MD; Karyn A. Goodman, MD; Theodore S. Hong, MD; Salma K. Jabbour, MD; William E. Jones, III, MD; Andre A. Konski, MD; Albert C. Koong, MD; Rachit Kumar, MD; Miguel Rodriguez-Bigas, MD; William Small Jr, MD; Charles R. Thomas Jr, MD; W. Warren Suh, MD (<em>Panel Chair</em>)</p></div></p>
                        <h3><a href="#">Financial Disclosures/Conflicts of Interest</a></h3>
                    <p><div class="content_para"><p>Not stated</p></div></p>
                        <h3><a href="#">Guideline Status</a></h3>
                    <p><div class="content_para"><p>This is the current release of the guideline.</p>
<p>This guideline updates a previous version: Blackstock AW, Russo SM, Konski AA, Suh WW, Cosman BC, Herman J, Mohiuddin M, Poggi MM, Regine WF, Saltz L, Small W Jr, Zook J, Expert Panel on Radiation Oncology-Rectal/Anal Cancer. ACR Appropriateness Criteria&reg; local excision in early-stage rectal cancer. [online publication]. Reston (VA): American College of Radiology (ACR); 2010. 5 p. [36 references]</p></div></p>
                        <h3><a href="#">Guideline Availability</a></h3>
                    <p><div class="content_para"><p>Available from the <a href="/web/20180712201305/https://www.guideline.gov/Home/Disclaimer?id=48298&amp;contentType=summary&amp;redirect=https%3a%2f%2facsearch.acr.org%2fdocs%2f69500%2fNarrative%2f" title="ACR Web site">American College of Radiology (ACR) Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180712201305im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>.</p></div></p>
                        <h3><a href="#">Availability of Companion Documents</a></h3>
                    <p><div class="content_para"><p>The following are available:</p>
<ul style="list-style-type: disc;">
    <li>ACR Appropriateness Criteria&reg;. Overview. Reston (VA): American College of Radiology; 2 p. Available from the <a href="/web/20180712201305/https://www.guideline.gov/Home/Disclaimer?id=48298&amp;contentType=summary&amp;redirect=http%3a%2f%2fwww.acr.org%2f%7e%2fmedia%2fACR%2fDocuments%2fAppCriteria%2fOverview.pdf" title="ACR Web site">American College of Radiology (ACR) Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180712201305im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>. </li>
    <li>ACR Appropriateness Criteria&reg;. Literature search process. Reston (VA): American College of Radiology; 1 p. Available from the <a href="/web/20180712201305/https://www.guideline.gov/Home/Disclaimer?id=48298&amp;contentType=summary&amp;redirect=http%3a%2f%2fwww.acr.org%2f%7e%2fmedia%2fACR%2fDocuments%2fAppCriteria%2fLiteratureSearchProcess.pdf" title="ACR Web site">ACR Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180712201305im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>. </li>
    <li>ACR Appropriateness Criteria&reg;. Evidence table development. Reston (VA): American College of Radiology; 2015 Nov. 5 p. Available from the <a href="/web/20180712201305/https://www.guideline.gov/Home/Disclaimer?id=48298&amp;contentType=summary&amp;redirect=https%3a%2f%2fwww.acr.org%2f%7e%2fmedia%2fACR%2fDocuments%2fAppCriteria%2fEvidenceTableDevelopment.pdf%3fdb%3dweb" title="ACR Web site">ACR Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180712201305im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>. </li>
    <li>ACR Appropriateness Criteria&reg; local excision in rectal cancer. Evidence table. Reston (VA): American College of Radiology; 2014. 23 p. Available from the <a href="/web/20180712201305/https://www.guideline.gov/Home/Disclaimer?id=48298&amp;contentType=summary&amp;redirect=https%3a%2f%2facsearch.acr.org%2fdocs%2f69500%2fEvidenceTable%2f" title="ACR Web site">ACR Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180712201305im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>. </li>
</ul></div></p>
                        <h3><a href="#">Patient Resources</a></h3>
                    <p><div class="content_para"><p>None available</p></div></p>
                        <h3><a href="#">NGC Status</a></h3>
                    <p><div class="content_para"><p>This NGC summary was completed by ECRI Institute on August 13, 2009. This summary was updated by ECRI Institute on January 11, 2011 and August 14, 2014.</p></div></p>
                        <h3><a href="#">Copyright Statement</a></h3>
                    <p><div class="content_para"><p>Instructions for downloading, use, and reproduction of the American College of Radiology (ACR) Appropriateness Criteria&reg; may be found on the <a href="/web/20180712201305/https://www.guideline.gov/Home/Disclaimer?id=48298&amp;contentType=summary&amp;redirect=http%3a%2f%2fwww.acr.org%2fQuality-Safety%2fAppropriateness-Criteria%2fTermsConditions" title="ACR Web site">ACR Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180712201305im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>.</p></div></p>

            </div>
                <h2 id="99999" class="accordion-title section-99999 is-active" role="tab" aria-expanded="true"><a href="#">Disclaimer</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">NGC Disclaimer</a></h3>
                    <p><p>The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.</p> 
<p>All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.</p> 
<p>Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the <a href="/web/20180712201305/https://www.guideline.gov/help-and-about/summaries/inclusion-criteria">NGC Inclusion Criteria</a>.</p> 
<p>NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding guideline content are directed to contact the guideline developer.</p></p>

            </div>

    </div>
    <!-- /.accordion-container -->

<!-- ASIDE -->
<!-- FOOTER -->






		</div><!-- /.article -->

	</div><!-- /.content -->

	
			<div class="aside">
				

    <!-- About NGC -->
    <div class="info-block">
            <h3 class="info prefix-icon large-icon">About NGC Guideline Summaries</h3>
            <p>NGC provides structured summaries containing information from clinical practice guidelines.</p>
            <ul>
                <li><a href="/web/20180712201305/https://www.guideline.gov/help-and-about/summaries/inclusion-criteria" class="internal-link">Inclusion Criteria</a></li>
                <li><a href="/web/20180712201305/https://www.guideline.gov/help-and-about/summaries/template-of-guideline-attributes" class="internal-link">Template of Guideline Attributes</a></li>
                <li><a href="/web/20180712201305/https://www.guideline.gov/help-and-about/summaries/classification-scheme" class="internal-link">Classification Scheme</a></li>
            </ul>
            <p><a href="/web/20180712201305/https://www.guideline.gov/help-and-about/summaries/faqs" class="help-button">Guideline Summary FAQs</a></p>

    </div>
    <!-- /info-block -->

    <!-- Guideline Synthesis -->

    <!-- HHS Block -->

    <!-- Related Content -->


    <hr>

    <!-- New on NGC -->
    <div class="subscribe-header">
        <h3 class="subscribe-title">New on NGC</h3>
        <ul class="subscribe-links">
            <li><a href="/web/20180712201305/https://www.guideline.gov/subscribe" class="newsletter"><span class="subscribe-links-label">Get Email Alerts</span></a></li>
            <li><a href="/web/20180712201305/https://www.guideline.gov/rssFiles/ngc_newthisweek.xml" class="rss"><span class="subscribe-links-label">RSS Feed</span></a></li>
        </ul>
    </div>
    <!-- /.subscribe-header -->
        <h5 class="prefix-icon guideline news-list-category-label">Guideline Summaries</h5>
        <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011378</li>
            <li>2017 Oct</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180712201305/https://www.guideline.gov/summaries/summary/51300/mental-health-care-in-the-perinatal-period-australian-clinical-practice-guideline">Mental health care in the perinatal period: Australian clinical practice guideline.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011372</li>
            <li>2015</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180712201305/https://www.guideline.gov/summaries/summary/51294/clinical-practice-guideline-on-systemic-lupus-erythematosus">Clinical practice guideline on systemic lupus erythematosus.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011385</li>
            <li>2018 Mar</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180712201305/https://www.guideline.gov/summaries/summary/51326/vadod-clinical-practice-guideline-for-the-management-of-pregnancy">VA/DoD clinical practice guideline for the management of pregnancy.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011376</li>
            <li>2018 Feb</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180712201305/https://www.guideline.gov/summaries/summary/51298/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-dihydropyrimidine-dehydrogenase-genotype-and-fluoropyrimidine-dosing-2017-update">Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011370</li>
            <li>2017 Dec</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180712201305/https://www.guideline.gov/summaries/summary/51292/the-implementation-of-targeted-temperature-management-an-evidencebased-guideline-from-the-neurocritical-care-society">The implementation of targeted temperature management: an evidence-based guideline from the Neurocritical Care Society.</a></p>
    </div>

    <a class="block-link" href="/web/20180712201305/https://www.guideline.gov/new-this-week/index">
        <h3>New This Week </h3>
        <p>View more and sign up for our Newsletter</p>
    </a>
    <!-- Adobe Reader -->
    <p><a href="/web/20180712201305/https://www.guideline.gov/disclaimer?id=48298&amp;contentType=summary&amp;redirect=http%3A%2F%2Fget.adobe.com%2Freader%2F" class="external-link">Get Adobe Reader</a></p>

			</div><!-- /.aside -->
		</div><!-- /.aside-container -->

	<!-- BACK TO TOP -->
	
	
	



    <!-- COMMENTS -->
    

</div><!-- /.main -->

	</main>

	<!-- FOOTER -->
	<div class="footer" id="footer">

		<div class="footer-grid-container">
			<!-- Header -->
			<div class="footer-header">
				<a href="#" class="footer-logo">
			 		<picture>
					  	<source type="image/svg+xml" srcset="/web/20180712201305im_/https://www.guideline.gov/UI/images/logo_NGC_footer.svg">
					  	<img src="/web/20180712201305im_/https://www.guideline.gov/UI/images/logo_NGC_footer.png" alt="NGC">
					</picture>
				</a>
			</div><!-- /.footer-header -->

			<!-- Content -->
			<div class="footer-content">
				<div class="footer-nav">
					<ul class="level-1">
						<li><a href="/web/20180712201305/https://www.guideline.gov/">Home</a></li>
		                <li><a href="/web/20180712201305/https://www.guideline.gov/new-this-week/index">New This Week</a></li>
						<li><a href="/web/20180712201305/https://www.guideline.gov/browse/organization" class="parent-link">Guideline Summaries</a></li>
<li><a href="/web/20180712201305/https://www.guideline.gov/syntheses/index">Guideline Syntheses</a></li>						<li><a href="/web/20180712201305/https://www.guideline.gov/expert">Expert Commentaries</a></li>
		                <li><a href="/web/20180712201305/https://www.guideline.gov/matrix">Matrix Tool</a></li>
						<li><a href="/web/20180712201305/https://www.guideline.gov/summaries/submit">Submit Guidelines</a></li>
						<li><a href="/web/20180712201305/https://www.guideline.gov/help-and-about">Help &amp;&nbsp;About</a></li>
					</ul>
					<ul class="level-2">
						<li><a href="/web/20180712201305/https://www.guideline.gov/contact-us">Contact Us</a></li>
						<li><a href="/web/20180712201305/https://www.guideline.gov/rss">RSS</a></li>
					    <li><a href="/web/20180712201305/https://www.guideline.gov/site-map">Site Map</a></li>
                        <li><a href="/web/20180712201305/https://www.guideline.gov/browse/related">Related NQMC Measures</a></li>
                        <li><a href="/web/20180712201305/https://www.guideline.gov/help-and-about/about/editorial-board">Editorial Board</a></li>
                        <li><a href="/web/20180712201305/https://www.guideline.gov/help-and-about/general/web-site-credits">Web Site Credits</a></li>
                        <li><a href="/web/20180712201305/https://www.guideline.gov/help-and-about/general/disclaimer">Disclaimer</a></li>
						<li><a href="/web/20180712201305/https://www.guideline.gov/help-and-about/general/privacy">Privacy Policy</a></li>
                        <li><a href="/web/20180712201305/https://www.guideline.gov/help-and-about/technical/accessibility">Accessibility</a></li>	
                        <li><a href="/web/20180712201305/https://www.guideline.gov/help-and-about/technical/for-web-developers">For Web Developers</a></li>
					</ul>
				</div><!-- /.footer-nav -->
			</div><!-- /.footer-content -->

			<!-- Aside -->
			<div class="footer-aside">
				<h5 class="footer-partner-link-header">Visit our partner sites</h5>
				<ul class="footer-partner-links">
				    <li><!-- NQMC footer link -->
						<a href="https://web.archive.org/web/20180712201305/https://www.qualitymeasures.ahrq.gov/" target="_blank" class="partner-button nqmc">
							<span class="partner-logo">
								<picture>
							    	<source type="image/svg+xml" srcset="/web/20180712201305im_/https://www.guideline.gov/UI/images/logo_footerlink_nqmc.svg">
									<img src="/web/20180712201305im_/https://www.guideline.gov/UI/images/logo_footerlink_nqmc.png" alt="National Quality Measures Clearinghouse"/>
								</picture>
							</span>
						</a>
					</li><!--/MQMC footer Link -->
					<li><!-- HHS footer link --> 
						<a href="https://web.archive.org/web/20180712201305/https://www.qualitymeasures.ahrq.gov/hhs/index.aspx" target="_blank" class="partner-button hhs">
							<span class="partner-logo">
								<picture>
								    <source type="image/svg+xml" srcset="/web/20180712201305im_/https://www.guideline.gov/UI/images/logo_footerlink_hmis.svg">
								    <img src="/web/20180712201305im_/https://www.guideline.gov/UI/images/logo_footerlink_hmis.png" alt="HHS Measures Inventory"/>
								</picture>
							</span>
						</a>
					</li><!--/HHS footer link -->
				</ul>
			</div><!-- /.footer-aside -->

		</div><!-- /.footer-grid-container -->

	</div><!-- /.footer -->

	
	<!-- AHRQ FOOTER -->
	<div id="ahrq-footer">

		<!-- FIRST -->
		<div class="ahrq-first-footer">
			<div class="column">
			<div class="ahrq-footer-grid-container">
				<div class="ahrq-footer-left">
					<p><a href="https://web.archive.org/web/20180712201305/http://www.ahrq.gov/index.html" class="ahrq-footer-logo" target="_blank">AHRQ</a></p>
				</div><!-- /.ahrq-footer-left -->
				<div class="ahrq-footer-center">
					<ul>
						<li><a href="https://web.archive.org/web/20180712201305/http://www.ahrq.gov/policy/electronic/accessibility/index.html" target="_blank">Accessibility</a></li>
						<li><a href="https://web.archive.org/web/20180712201305/http://www.ahrq.gov/policy/electronic/disclaimers/index.html" target="_blank">Disclaimers</a></li>
						<li><a href="https://web.archive.org/web/20180712201305/http://www.ahrq.gov/policy/eeo/index.html" target="_blank">EEO</a></li>
						<li><a href="https://web.archive.org/web/20180712201305/http://www.ahrq.gov/policy/foia/index.html" target="_blank">FOIA</a></li>
						<li><a href="https://web.archive.org/web/20180712201305/http://www.hhs.gov/web/governance/digital-strategy/index.html" target="_blank">HHS Digital Strategy</a></li>
						<li><a href="https://web.archive.org/web/20180712201305/http://oig.hhs.gov/" target="_blank">Inspector General</a></li>
						<li><a href="https://web.archive.org/web/20180712201305/http://www.ahrq.gov/policy/electronic/plain-writing/index.html" target="_blank">Plain Writing Act</a></li>
						<li><a href="https://web.archive.org/web/20180712201305/http://www.ahrq.gov/policy/electronic/privacy/index.html" target="_blank">Privacy Policy</a></li>
						<li><a href="https://web.archive.org/web/20180712201305/http://www.ahrq.gov/policy/electronic/about/policyix.html" target="_blank">Electronic Policies</a></li>
						<li><a href="https://web.archive.org/web/20180712201305/http://www.hhs.gov/plugins.html" target="_blank">Viewers &amp; Players</a></li>
					</ul>
				</div><!-- /.ahrq-footer-center -->
				<div class="ahrq-footer-right">
					<h3>Get Social</h3>
					<ul class="ahrq-social">
						<li><a href="https://web.archive.org/web/20180712201305/http://www.facebook.com/" target="_blank" class="facebook"><span class="screen-reader-text">Facebook</span></a></li>
						<li><a href="https://web.archive.org/web/20180712201305/http://www.twitter.com/" target="_blank" class="twitter"><span class="screen-reader-text">Twitter</span></a></li>
						<li><a href="https://web.archive.org/web/20180712201305/http://www.linkedin.com/" target="_blank" class="linkedin"><span class="screen-reader-text">LinkedIn</span></a></li>
						<li><a href="https://web.archive.org/web/20180712201305/http://www.youtube.com/" target="_blank" class="youtube"><span class="screen-reader-text">YouTube</span></a></li>
					</ul>
				</div><!-- /.ahrq-footer-right -->
			</div><!-- /.ahrq-footer-grid-container -->
			</div><!-- /.column -->
		</div><!-- /.first-footer -->

		<!-- SECOND -->
		<div class="ahrq-second-footer">
			<div class="column">
			<div class="ahrq-footer-grid-container">
				<div class="ahrq-footer-left">
					<ul>
						<li><a href="https://web.archive.org/web/20180712201305/http://www.ahrq.gov/index.html" target="_blank" class="ahrq-footer-home-link"><span class="screen-reader-text">AHRQ Home</span></a></li>
						<li><a href="https://web.archive.org/web/20180712201305/http://www.ahrq.gov/cpi/about/index.html" target="_blank">About Us</a></li>
						<li><a href="https://web.archive.org/web/20180712201305/http://www.ahrq.gov/cpi/about/careers/index.html" target="_blank">Careers</a></li>
						<li><a href="https://web.archive.org/web/20180712201305/http://www.ahrq.gov/contact/index.html" target="_blank">Contact Us</a></li>
						<li><a href="https://web.archive.org/web/20180712201305/http://www.ahrq.gov/Sitemap.html" target="_blank">Sitemap</a></li>
						<li><a href="https://web.archive.org/web/20180712201305/https://info.ahrq.gov/" target="_blank">FAQ</a></li>
					</ul>	
				</div><!-- /.ahrq-footer-left -->
				<div class="ahrq-footer-center">
					<ul>
						<li><a href="https://web.archive.org/web/20180712201305/http://www.ahrq.gov/health-care-information/index.html" target="_blank">Health Care Information</a></li>
						<li><a href="https://web.archive.org/web/20180712201305/http://www.ahrq.gov/patients-consumers/index.html" target="_blank">For Patients &amp; Consumers</a></li>
						<li><a href="https://web.archive.org/web/20180712201305/http://www.ahrq.gov/professionals/index.html" target="_blank">For Professionals</a></li>
						<li><a href="https://web.archive.org/web/20180712201305/http://www.ahrq.gov/policymakers/index.html" target="_blank">For Policymakers</a></li>
						<li><a href="https://web.archive.org/web/20180712201305/http://www.ahrq.gov/research/index.html" target="_blank">Research Tools &amp; Data</a></li>
						<li><a href="https://web.archive.org/web/20180712201305/http://www.ahrq.gov/funding/index.html" target="_blank">Funding &amp; Grants</a></li>
						<li><a href="https://web.archive.org/web/20180712201305/http://www.ahrq.gov/cpi/index.html" target="_blank">Offices, Centers &amp; Programs</a></li>
						<li><a href="https://web.archive.org/web/20180712201305/http://www.ahrq.gov/news/index.html" target="_blank">News &amp; Events</a></li>
					</ul>
				</div><!-- /.ahrq-footer-center -->
				<div class="ahrq-footer-right">
					<ul>
						<li><a href="https://web.archive.org/web/20180712201305/http://www.hhs.gov/" target="_blank">U.S. Department of Health &amp; Human Services</a></li>
						<li><a href="https://web.archive.org/web/20180712201305/http://www.whitehouse.gov/" target="_blank">The White House</a></li>
						<li><a href="https://web.archive.org/web/20180712201305/http://www.usa.gov/" target="_blank">USA.gov: The U.S. Government's Official Web Portal   </a></li>
					</ul>
					<p class="ahrq-address">
						<strong>Agency for Healthcare Research&nbsp;and&nbsp;Quality</strong>
					    <br/>5600 Fishers Lane
					    <br/>Rockville, MD 20857
					    <br/><strong>Telephone:</strong> (301) 427-1364
					</p>
				</div><!-- /.ahrq-footer-right -->
			</div><!-- /.ahrq-footer-grid-container -->
			</div><!-- /.column -->
		</div><!-- /.second-footer -->
	</div><!-- /#ahrq-footer -->


	
	<!-- SCRIPTS -->
	
<script src="//web.archive.org/web/20180712201305js_/https://ajax.googleapis.com/ajax/libs/jquery/1.6.3/jquery.min.js" type="text/javascript"></script>
<script type="text/javascript">
if(!window.jQuery){
document.write('<script src="/cassette.axd/script/cdd67f922f9d413eaccb759182297335f87c3ff7/UI/js/jquery.js" type="text/javascript"><\/script>');
}
</script>
<script src="/web/20180712201305js_/https://www.guideline.gov/cassette.axd/script/595952c286b7fd52f0737b6f62085709be93156a/bodyJS" type="text/javascript"></script>

    
</body>
</html>
<!--
     FILE ARCHIVED ON 20:13:05 Jul 12, 2018 AND RETRIEVED FROM THE
     INTERNET ARCHIVE ON 17:11:01 Jul 15, 2018.
     JAVASCRIPT APPENDED BY WAYBACK MACHINE, COPYRIGHT INTERNET ARCHIVE.

     ALL OTHER CONTENT MAY ALSO BE PROTECTED BY COPYRIGHT (17 U.S.C.
     SECTION 108(a)(3)).
-->
<!--
playback timings (ms):
  LoadShardBlock: 1155.296 (3)
  esindex: 0.01
  captures_list: 1184.286
  CDXLines.iter: 17.052 (3)
  PetaboxLoader3.datanode: 88.652 (4)
  exclusion.robots: 0.229
  exclusion.robots.policy: 0.216
  RedisCDXSource: 0.941
  PetaboxLoader3.resolve: 1265.578 (2)
  load_resource: 232.012
-->